Autolus Therapeutics PLC (AUTL)
2.84
+0.04
(+1.43%)
USD |
NASDAQ |
Nov 21, 16:00
2.86
+0.02
(+0.70%)
After-Hours: 20:00
Autolus Therapeutics Enterprise Value: 98.72M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 98.72M |
| November 20, 2024 | 88.07M |
| November 19, 2024 | 127.99M |
| November 18, 2024 | 138.64M |
| November 15, 2024 | 162.59M |
| November 14, 2024 | 143.96M |
| November 13, 2024 | 218.47M |
| November 12, 2024 | 229.12M |
| November 11, 2024 | 277.02M |
| November 08, 2024 | 335.57M |
| November 07, 2024 | 418.05M |
| November 06, 2024 | 292.97M |
| November 05, 2024 | 242.41M |
| November 04, 2024 | 231.76M |
| November 01, 2024 | 274.34M |
| October 31, 2024 | 239.75M |
| October 30, 2024 | 407.40M |
| October 29, 2024 | 497.88M |
| October 28, 2024 | 553.77M |
| October 25, 2024 | 524.49M |
| October 24, 2024 | 524.49M |
| October 23, 2024 | 532.48M |
| October 22, 2024 | 524.49M |
| October 21, 2024 | 545.78M |
| October 18, 2024 | 620.30M |
| Date | Value |
|---|---|
| October 17, 2024 | 593.68M |
| October 16, 2024 | 543.12M |
| October 15, 2024 | 476.59M |
| October 14, 2024 | 455.30M |
| October 11, 2024 | 444.66M |
| October 10, 2024 | 436.68M |
| October 09, 2024 | 402.08M |
| October 08, 2024 | 423.37M |
| October 07, 2024 | 383.45M |
| October 04, 2024 | 402.08M |
| October 03, 2024 | 380.79M |
| October 02, 2024 | 399.42M |
| October 01, 2024 | 300.96M |
| September 30, 2024 | 308.94M |
| September 27, 2024 | 259.98M |
| September 26, 2024 | 220.07M |
| September 25, 2024 | 212.09M |
| September 24, 2024 | 228.05M |
| September 23, 2024 | 225.39M |
| September 20, 2024 | 286.59M |
| September 19, 2024 | 318.52M |
| September 18, 2024 | 323.85M |
| September 17, 2024 | 315.86M |
| September 16, 2024 | 358.44M |
| September 13, 2024 | 379.73M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-83.08M
Minimum
Jun 15 2022
1.502B
Maximum
Mar 20 2024
278.47M
Average
247.76M
Median
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 26.67M |
| Biodexa Pharmaceuticals PLC | -3.355M |
| NuCana PLC | -11.87M |
| TC BioPharm (Holdings) PLC | -0.927M |
| Bicycle Therapeutics PLC | 508.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -82.09M |
| Total Expenses (Quarterly) | 67.65M |
| EPS Diluted (Quarterly) | -0.31 |
| Earnings Yield | -42.96% |
| Normalized Earnings Yield | -42.26 |